Table 3.

Safety of treatment in three prospective, double-blind, placebo-controlled SGLT2 inhibitor trials in type 1 diabetic patients

First author, year	Treatment (mg/day)	Documented hypoglycemia	Serious DKA (n)	Genital infections (n)	UTI (n)	Volume depletion (n)
Henry (2015) [16]	Canagliflozin 300, canagliflozin 100, placebo	No difference between Rx vs placebo	7 vs 5 vs 0	11 vs 2 vs 3	6 vs 5 vs 2	1 vs 4 vs 0
Dandona (2017) [17]	Dapagliflozin 10, dapagliflozin 5, placebo	No difference between Rx vs placebo	4 vs 5 vs 3	34 vs 33 vs 7	19 vs 11 vs 13	0 vs 1 vs 2
Garg (2017) [18]	Sotagliflozin 400, placebo	No difference between Rx vs placebo	21 vs 4	45 vs 15	25 vs 27	13 vs 2